期刊文献+

PI3K/AKT信号通路在乳腺癌中的表达及其意义 被引量:4

Expression of PI3K/AKT signal pathway in breast cancer and the clinical significance
原文传递
导出
摘要 目的探讨人乳腺癌及正常乳腺组织中P-AKT的表达及其意义,为乳腺癌的早期临床诊断和治疗提供理论和实验依据。方法采用Western blot及RT-PCR方法检测100份乳腺癌组织标本和30份正常乳腺组织标本中P-AKT蛋白及mRNA的表达情况,并进一步探讨其与乳腺癌临床病理指标的相关性。结果 P-AKT蛋白及mRNA在乳腺癌中的表达水平高于在正常乳腺组织中的表达水平,且P-AKT蛋白及mRNA的表达与临床分期相关(P<0.05),而与年龄、肿瘤直径、淋巴结转移和组织学分级无关(P>0.05)。结论 PI3K/AKT信号通路可能参与乳腺癌的发生发展,在癌变过程中起着重要作用。 Objective:To explore the expressions of p-AKT in human breast cancer and normal breast tissue and the significance,provide theoretical and experimental basis for early clinical diagnosis and treatment of breast cancer.Methods:Western blot and RT-PCR were used to detect the expressions of p-AKT protein and mRNA in 100 cases with breast cancer and 30 cases with normal breast tissue,its correlation with clinicopathological indexes of breast cancer was further researched.Results:The expression levels of p-AKT protein and mRNA in breast cancer were statistically significantly higher than those in normal breast tissue.The expressions of p-AKT protein and mRNA were correlated with clinical staging(P〈0.05),but it was not correlated with age,diameter of breast cancer,lymph node metastasis,and histological grading(P〈0.05).Conclusion:PI3 K / AKT signal pathway may be involved in oncogenesis and development of breast cancer,which plays an important role in the course of cancerization.
出处 《中国妇幼保健》 CAS 2015年第20期3475-3478,共4页 Maternal and Child Health Care of China
基金 河北省卫生厅计划指导项目〔ZD20140360〕
关键词 乳腺癌 P-AKT WESTERN BLOT RT-PCR Breast cancer p-AKT Western blot RT-PCR
  • 相关文献

参考文献10

  • 1Shaw RJ,Cantley LC.Ras,PI(3)K and m TOR signaling controls tumour cell growth[J].Nature,2006,441(7092):424-430.
  • 2Katso R,Okkenhaug K,Ahmadi K,et al.Cellular function of phosphoinositide 3-kinases:implications for development,homeostasis,and cancer[J].Annu Rev Cell Dev Biol,2001,17:615-675.
  • 3李建,周怀君.PI3K/Akt信号通路在肿瘤研究中的进展[J].东南大学学报(医学版),2014,33(3):392-395. 被引量:31
  • 4Maira SM,Finan P,Garcia-echeverri AC.From the bench to the bed side:PI3K pathway inhibitors in clinical development[J].Curr Top Microbiol Immunol,2010,347:209-239.
  • 5万军,车云,康宁宁.信号通路蛋白Akt1、ERK1/2与HIF-1α在肺癌组织中的表达及其临床意义[J].实用癌症杂志,2014,29(12):1515-1517. 被引量:16
  • 6Zhang Y,Yao X,Jiang C,et al.Expression of PI3K,PTEN and AKT in small intestinal adenocarcinoma detected by quantum dots-based immunofluorescence technology[J].Cancer Biomark,2013,13(4):299-305.
  • 7彭雅亚.AKT-1在乳腺良恶性病变中的表达及其临床意义[J].长沙医学院学报,2014(3):19-22. 被引量:5
  • 8Quan JH,Chang,Zho UW,et al.Involvement of PI3k inase/AKT-dependent Bad phosphorylation in Toxoplasmagondi imediated in hibition of host cell apoptosis[J].Exp Parasitol,2013,133(4):462-471.
  • 9Vunt,Parkma,Shult ZJC,et al.hn RNPU enhances caspase-9 splicingan dismo dulated by AKT-dependent phosphory lation of hn RNPL[J].J Biol Chem,2013,288(12):8575-8584.
  • 10刁存启,毕经旺,王宝成.Akt信号分子和结直肠癌的关系[J].中国肿瘤生物治疗杂志,2014,21(5):584-588. 被引量:8

二级参考文献47

  • 1苗丽君,王静.Akt与肿瘤的研究进展[J].国外医学(生理病理科学与临床分册),2004,24(5):406-409. 被引量:38
  • 2ENGELMAN J A, LUO J, CANTLEY L C, et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism[ J]. Nat Rev Genet,2006,7:606-619.
  • 3ODA K, STOKOE D, TAKETANI Y, et al. High frequency of coexistent mutations of PIK3CA and PTEN genes inendometri- al carcinoma[ J ]. Cancer Res ,2005,65 ( 23 ) : 10669-10673.
  • 4SHAW R J,CANTLEY L C. Ras,PI(3)K and mTOR signaling controls tumour cell growth [ J ]. Nature, 2006,441 ( 7092 ) : 424-430.
  • 5KATSO R, OKKENHAUG K, AHMADI K, et al. Cellular func- tion of phosphoinositide 3-kinases: implications for develop- ment,homeostasis,and cancer [ J ]. Annu Rev Cell Dev Biol, 2001,17:615-675.
  • 6ZHAO L, VOGT P K. Class I PI3K in oncogenic cellular trans- formation[ J ]. Oncogene ,2008,27 ( 41 ) :5486-5496.
  • 7LEE H T, KAY E P. Regulatory role of cAMP on expression of Cdk4 and p27 ( Kipl ) by inhibiting phosphatidylionositol 3- ki- nase in corneal endothelial cells [ J ]. Invest Ophthalmol Vis Sci,2003,44(9) :3816-3825.
  • 8MAIRA S M,FINAN P,GARCIA-ECHEVERRIA C. From the bench to the bed side:PI3K pathway inhibitors in clinical de- velopment [ J ]. Curr Top Microbiol Immunol, 2010, 347: 209- 239.
  • 9WARD S G,FINAN P. Isoform-specific phosphoinesitide 3-ki-nase inhibitors as therapeutic agents [ J ]. Current Opinion In Phammaology, 2003,3 ( 4 ) : 426 - 434.
  • 10ENGELMAN J A, LUO J, CANTLEY L C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and me- tabolism [ J ]. Nat Rev Genet ,2006,7:606-619.

共引文献52

同被引文献33

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部